Dianthus Therapeutics (Dianthus Therapeutics) Change In Payables And Accrued Expense : $-1.38 Mil (TTM As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Dianthus Therapeutics Change In Payables And Accrued Expense?

Dianthus Therapeutics's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2024 was $-2.99 Mil. It means Dianthus Therapeutics's Accounts Payable & Accrued Expense declined by $2.99 Mil from Dec. 2023 to Mar. 2024 .

Dianthus Therapeutics's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was $0.66 Mil. It means Dianthus Therapeutics's Accounts Payable & Accrued Expense increased by $0.66 Mil from Dec. 2022 to Dec. 2023 .

Dianthus Therapeutics Change In Payables And Accrued Expense Historical Data

The historical data trend for Dianthus Therapeutics's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dianthus Therapeutics Change In Payables And Accrued Expense Chart

Dianthus Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

4.92

2.28

0.66

Dianthus Therapeutics Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Change In Payables And Accrued Expense	Get a 7-Day Free Trial			2.03	-4.73	-	1.60	-2.99

Dianthus Therapeutics Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.38 Mil.

Dianthus Therapeutics Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Dianthus Therapeutics's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Dianthus Therapeutics (Dianthus Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dianthus Therapeutics Inc (NAS:DNTH) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

87E:Germany

Address

7 Times Square, 43rd Floor, New York, NY, USA, 10036

Website

https://www.dianthustx.com

Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is comprised of an experienced team of biotech and pharma executives who are leading the next generation of antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune diseases.

Dianthus Therapeutics (Dianthus Therapeutics) Headlines

From GuruFocus

Fairmount Funds Management LLC Acquires New Stake in Dianthus Therapeutics Inc

By GuruFocus Research • 09-29-2023

Insider Buying: Fairmount Funds Management LLC Acquires 24,254 Shares of Dianthus Therapeutics Inc

By GuruFocus Research • 09-14-2023